Literature DB >> 25651430

Strong expression of EZH2 and accumulation of trimethylated H3K27 in diffuse large B-cell lymphoma independent of cell of origin and EZH2 codon 641 mutation.

Zheng Zhou1, Juehua Gao2, Relja Popovic1, Kristy Wolniak2, Vamsi Parimi2, Jane N Winter1, Jonathan D Licht1, Yi-Hua Chen2.   

Abstract

Gain-of-function EZH2 mutation promotes H3K27 trimethylation (H3K27me3) and lymphoid transformation of germinal center (GC) derived B-cell lymphoma, such as GCB diffuse large B-cell lymphoma (DLBCL), but not activated B-cell (ABC) DLBCL. It is unclear whether expression levels of EZH2 and consequential H3K27me3 vary by EZH2 mutation and/or cell-of-origin in DLBCL. Ninety lymphoma samples including 40 DLBCLs were studied by immunohistochemistry. EZH2 Y641 mutations were detected in three of 20 (15%) GCB and none of 20 ABC types. All 40 DLBCLs showed strong EZH2, expression with high-level H3K27me3 in 90% GCBs and 95% ABCs. In 50 other B-cell lymphomas except for follicular lymphoma, strong EZH2 expression correlated with high-grade features. Immunoblot of DLBCL cell lines and microarray gene expression study of EZH2 in B-cell lymphomas were consistent with the immunohistochemistry findings. High-level EZH2 and H3K27me3 were common in DLBCL independent of cell-of-origin and EZH2 mutation. High-level EZH2 in lymphoma of aggressive features suggests additional therapeutic targets.

Entities:  

Keywords:  Lymphoid malignancies; histopathology; mutation detection

Mesh:

Substances:

Year:  2015        PMID: 25651430     DOI: 10.3109/10428194.2015.1006220

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  8 in total

1.  Concomitant 1p36 deletion and TNFRSF14 mutations in primary cutaneous follicle center lymphoma frequently expressing high levels of EZH2 protein.

Authors:  Ambrus Gángó; Bence Bátai; Martin Varga; Dóra Kapczár; Gergő Papp; Márta Marschalkó; Enikő Kuroli; Tamás Schneider; Judit Csomor; András Matolcsy; Csaba Bödör; Ágota Szepesi
Journal:  Virchows Arch       Date:  2018-06-01       Impact factor: 4.064

2.  EBV-negative aggressive NK-cell leukemia/lymphoma: a clinical and pathological study from a single institution.

Authors:  Juehua Gao; Amir Behdad; Peng Ji; Kristy L Wolniak; Olga Frankfurt; Yi-Hua Chen
Journal:  Mod Pathol       Date:  2017-05-26       Impact factor: 7.842

Review 3.  H3K27 Methylation: A Focal Point of Epigenetic Deregulation in Cancer.

Authors:  J N Nichol; D Dupéré-Richer; T Ezponda; J D Licht; W H Miller
Journal:  Adv Cancer Res       Date:  2016-06-17       Impact factor: 6.242

4.  Overexpression of EZH2 in multiple myeloma is associated with poor prognosis and dysregulation of cell cycle control.

Authors:  C Pawlyn; M D Bright; A F Buros; C K Stein; Z Walters; L I Aronson; F Mirabella; J R Jones; M F Kaiser; B A Walker; G H Jackson; P A Clarke; P L Bergsagel; P Workman; M Chesi; G J Morgan; F E Davies
Journal:  Blood Cancer J       Date:  2017-03-31       Impact factor: 11.037

5.  Mutant p53 induces EZH2 expression and promotes epithelial-mesenchymal transition by disrupting p68-Drosha complex assembly and attenuating miR-26a processing.

Authors:  Fei-Zhou Jiang; Yin-Yan He; Hui-Hui Wang; Hui-Lin Zhang; Jian Zhang; Xiao-Fang Yan; Xiao-Jun Wang; Qi Che; Jie-Qi Ke; Zheng Chen; Huan Tong; Yong-Li Zhang; Fang-Yuan Wang; Yi-Ran Li; Xiao-Ping Wan
Journal:  Oncotarget       Date:  2015-12-29

6.  EZH2 alterations in follicular lymphoma: biological and clinical correlations.

Authors:  S Huet; L Xerri; B Tesson; S Mareschal; S Taix; L Mescam-Mancini; E Sohier; M Carrère; J Lazarovici; O Casasnovas; L Tonon; S Boyault; S Hayette; C Haioun; B Fabiani; A Viari; F Jardin; G Salles
Journal:  Blood Cancer J       Date:  2017-04-21       Impact factor: 11.037

7.  Analysis of H3K27me3 expression and DNA methylation at CCGG sites in smoking and non-smoking patients with non-small cell lung cancer and their clinical significance.

Authors:  Kunshou Zhu; Yujie Deng; Guoxing Weng; Dan Hu; Cheng Huang; Keitaro Matsumoto; Takeshi Nagayasu; Takehiko Koji; Xiongwei Zheng; Wenhui Jiang; Gen Lin; Yibin Cai; Guibin Weng; Xiaohui Chen
Journal:  Oncol Lett       Date:  2018-02-21       Impact factor: 2.967

8.  Prognostic Value of Histone Modifying Enzyme EZH2 in RCHOP-Treated Diffuse Large B-Cell Lymphoma and High Grade B-Cell Lymphoma.

Authors:  Sara Petronilho; José Pedro Sequeira; Sofia Paulino; Paula Lopes; Susana Lisboa; Sérgio Chacim; João Lobo; Manuel Teixeira; Carmen Jerónimo; Rui Henrique
Journal:  J Pers Med       Date:  2021-12-18
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.